Dr Einav Nili Gal-Yam reports on a patient who had a remarkable complete NED response to lasofoxifene and remains NED at 88 weeks. Her ESR1 mutation also can no longer be detected. We need these type of options for HR+, HER2- MBC. #MBCRC22
Some brain mets develop at the same time as below the neck mets and others much later - and they’re not the same, at least in mice. (And I was too slow on the 📷 to capture the very nice slide 😩) #MBCRC22
A great idea to connect patients/advocates and researchers is the http://match.com/Tinder model - advocates and researchers have profiles, searchable and matchable. Now, who’s going to host this? #ResearchTinder #MBCRC22
More brilliant ideas from @bobriter: don’t have trainees present their work (they get too much into the weeds), have trainees share why they got into cancer research (researchers are people too!), have the advocates chose which poster/abstract is the most understandable #MBCRC22
I hope more institutions can emulate the program @bobriter started @Cornell to connect researchers and people living with cancer/community members. One brilliant idea: a 🛎 on the table dinged when the researchers/trainees get too technical. #MBCRC22
Grateful to know and work on projects with this incredible leader on advocates and researchers working together @HillStirSci #MBCRC22
In every model Dr McDonnell looked at the estrogen receptor has immunosuppressive, cancer promoting effects & SERDs reverse this. In melanoma adding immunotherapy to fulvestrant is effective and they’re opening a trial at Duke - and this could have utility in MBC as well #MBCRC22
Lasofoxifene, @SermonixPharma product, is a promising new SERM. Combo with abemeciclib (Verzenio) also looking good. (Disclosure: I do some consulting for Sermonix.) #MBCRC22
If you look at the bottom left of the graphs above, elacestrant sucks at degrading/downregulating the estrogen receptor BUT it’s still showing good results in trials and will likely be approved later this year. #MBCRC22
Where are we with SERMs and SERDs? Unfortunately of the 13 SERDs being looked at a year or so ago, the majority have fallen off the cliff. Degrading the receptor doesn’t necessarily correlate with ability to stop proliferation. #MBCRC22
Looking forward to this talk by a giant in hormone receptors, Dr Donald McDonnell (not to mention he has the BEST 🇮🇪 accent - I’d listen to him read the phone book!) #MBCRC22
Also glad she didn’t ☠️ @faceofstage4 with chocolate hidden in a marshmallow last night!! (WTF was chocolate doing in the middle of a marshmallow???) #MBCRC22
Thrilled to see @JaniceTNBCmets speaking today at #MBCRC22. She is a wonderful #advocate, friend, 🍷 buddy
CD8+ T cell localization is correlated with prognosis in TNBC - cold (no immune infiltration) is bad, inflamed/hot (lots of CD8+ T cells in the tumor bed) have a better outcome #MBCRC22
This heat map, of human data from @StoverLab, shows a clear difference in molecular profiles of TNBC between younger and older people #MBCRC22
The older we get the higher the risk of cancer. Our immune systems change - and not for the better - with age. Is the later the reason for the former? It’s likely at least a factor. #MBCRC22
Now up Dr @meburkard: his patient, Peg, who outlived 2 of her oncologists, inspired his work on exception responders - she has lived with MBC for 40 (FORTY!!!!) years 🤩 #MBCRC22
Dr Acosta, in mouse studies, has shown that metastasis inducing CTCs are formed during sleep, and that administration of melatonin can also do this- so, what does this mean for humans taking melatonin???? #MBCRC22
Dr Nicola Aceto reminds us that MBC really is a clusterf*** - clusters of circulating tumor cells (CTCs) are 50 times more metastatic than single CTCs. #MBCRC22
Summary of US AURORA results by Dr Susana Garcia-Recio. Half of good prognosis luminal A (HR+, HER2- usually) will eventually mutate to worse prognosis subtypes, so IMO we need to figure out when this is happening #MBCRC22
How useful is the type of information from AURORA? About 50% had actionable mutations but as I always say unless we study everyone we won’t know what’s important to focus on and what direction to go with drug development #MBCRC22
In AURORA only mutations in TP53 and LRP1B were associated with worse outcomes; analysis of first 375 patients - additional data might be available later this year. #MBCRC22
Dr Martine Picard talks about findings from the European AURORA study of molecular changes in MBC #MBCRC22
